WSI Starts Cardiovascular Intervention Business with UK Keymal... "Will Become a New Cash Cow"

WSI is making a full-scale entry into the cardiovascular intervention procedure business by starting an exclusive distribution contract with the UK-based company KIMAL PLC. The cardiovascular intervention procedure business is a new business area that WSI, specializing in spinal diseases, is newly promoting as a future growth engine.

On the 31st, WSI announced that it had signed an exclusive distribution contract in Korea with KIMAL, a UK medical device specialist, for catheters including PICC (Peripherally Inserted Central Vein Catheter).

Founded in 1964, KIMAL develops, manufactures, and distributes medical devices used in diagnostics, cardiovascular intervention procedures, customized procedure packs, radiology, kidney diseases, and oncology treatments and procedures. It supplies over 2 million procedure packs and cardiovascular intervention products to more than 70 countries worldwide. As it collaborates in sales and marketing with the global cardiovascular company Angio Dynamics, it is recognized for its technology and product excellence in the global market.

KIMAL's PICC Line™ is a CT Rated (capable of simultaneous CT imaging and drug infusion) peripherally inserted central venous catheter designed to withstand drug infusion at 5 ml (milliliters) per second and pressure up to 300 psi.

This medical consumable is a thin and flexible tube inserted from peripheral vessels to the central vein line to administer fluids, anticancer drugs, antibiotics, chemotherapy, parenteral nutrition, and pain management drugs for long-term treatment. It is designed with special materials to prevent infection and to facilitate installation and reach to the right atrium through the blood vessels.

To rapidly expand its cardiovascular intervention procedure business, WSI has recruited experts with extensive experience leading related businesses at domestic and international medical device companies such as Medtronic. It is preparing active marketing targeting cancer-related academic societies and building a dealership network.

A WSI official said, “As the number of cancer patients in Korea increases, the establishment of cancer specialty hospitals in tertiary general hospitals is also increasing, and accordingly, the demand for cancer-related equipment and treatment materials is rapidly rising. PICC is also an important treatment material used more than 150,000 times annually, with increasing applications and usage.”

He added, “Since most anticancer drugs are repeatedly administered through long-term intravenous blood vessels, securing venous access is a critical issue in cancer treatment. Starting with this exclusive distribution contract with KIMAL, whose products are globally recognized, we will target the domestic PICC market and expand our cardiovascular intervention procedure business area.”

This content was produced with the assistance of AI translation services.